Article

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL

2022-11-15

Abstract excerpt

Background Genome editing can overcome HLA barriers to generate 'off-the-shelf’ CAR T cell therapies. Despite the success of CAR-T cell therapies in B-cell malignancies, the expression of shared T cell antigens has constrained the development of CAR T cells targeting T-cell malignancies, due to T cell fratricide. Targeted base editing using CRISPR guided cytidine deamination mediates highly precise C→U→T conversio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 67bcbddd-9cd6-5dda-90b0-4e77d6724f5f
DOI: 10.1182/blood-2022-169114

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALLDOI 10.1182/blood-2022-169114Read

Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic LeukemiaSemantic proximity Read

Base-edited CAR T Cells for combinational therapy against T cell malignanciesSemantic proximity Read

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALLSemantic proximity Read

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphomaSemantic proximity Read

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.Semantic proximity Read

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity Read

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALLSemantic proximity Read

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cellsSemantic proximity Read

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells: Potency despite risk of translocationsSemantic proximity Read

The clinical potential of gene editing as a tool to engineer cell‐based therapeuticsSemantic proximity Read